Cenicriviroc Mesylate

• CAT Number: I012935
• CAS Number: 497223-28-6
• Molecular Formula: C₄₂H₅₆N₄O₇S₂
• Molecular Weight: 793.05
• Purity: ≥95%
• Target: CCR
• Solubility: DMSO
• IUPAC Name: (5E)-8-[4-(2-butoxyethoxy)phenyl]-1-(2-methylpropyl)-N-[4-[(S)-(3-propylimidazol-4-yl)methylsulfinyl]phenyl]-3,4-dihydro-2H-1-benzazocine-5-carboxamide;methanesulfonic acid
• InChI: InChI=1S/C41H52N4O4S.CH4O3S/c1-5-7-22-48-23-24-49-38-15-10-32(11-16-38)33-12-19-40-35(25-33)26-34(9-8-21-44(40)28-31(3)4)41(46)43-36-13-17-39(18-14-36)50(47)29-37-27-42-30-45(37)20-6-2;1-5(2,3)4/h10-19,25-27,30-31H,5-9,20-24,28-29H2,1-4H3,(H,43,46);1H3,(H,2,3,4)/b34-26+;/t50-;/m0./s1
• InChIKey: IXPBPUPDRDCRSY-YLZLUMLXSA-N
• SMILES: CCCCOCCOC1=CC=C(C=C1)C2=CC3=C(C=C2)N(CCCC(=C3)C(=O)NC4=CC=C(C=C4)S(=O)CC5=CN=CN5CCC)CC(C)C.CS(=O)(=O)O

Cenicriviroc Mesylate (Cat.No:I012935) is a small molecule drug used for the treatment of liver fibrosis and inflammation caused by nonalcoholic steatohepatitis (NASH). It acts as a dual antagonist of the chemokine receptors CCR2 and CCR5, which are involved in the recruitment and activation of inflammatory cells. By blocking these receptors, Cenicriviroc Mesylate reduces inflammation and fibrosis in the liver, potentially preventing disease progression. Clinical trials have shown promising results in improving liver function and reducing fibrosis in NASH patients.

Reference

[1]. Lefebvre E, et al. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS One. 2016 Jun 27;11(6):e0158156. [2]. Visseaux B, et al. Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates. PLoS One. 2015 Aug 6;10(8):e0134904.